Do quantitative levels of antispike‐IgG antibodies aid in predicting protection from SARS‐CoV‐2 infection? Results from a longitudinal study in a police cohort

In a COVID‐19 sero‐surveillance cohort study with predominantly healthy and vaccinated individuals, the objectives were (i) to investigate longitudinally the factors associated with the quantitative dynamics of antispike (anti‐S1) IgG antibody levels, (ii) to evaluate whether the levels were associa...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of medical virology Ročník 95; číslo 7; s. e28904 - n/a
Hlavní autori: Sendi, Parham, Widmer, Nadja, Branca, Mattia, Thierstein, Marc, Büchi, Annina Elisabeth, Güntensperger, Dominik, Blum, Manuel Raphael, Baldan, Rossella, Tinguely, Caroline, Heg, Dik, Theel, Elitza S., Berbari, Elie, Tande, Aaron J., Endimiani, Andrea, Gowland, Peter, Niederhauser, Christoph
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Wiley Subscription Services, Inc 01.07.2023
Predmet:
Antibodies
antispike‐IgG
COVID-19
Health risks
IgG antibody
Immunoglobulin G
Infections
Longitudinal studies
Police
Prediction models
quantitaive antispike‐IgG
Regression analysis
Regression models
SARS‐CoV‐2
serology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
Vaccination
Virology
COVID-19
quantitaive antispike-IgG
SARS-CoV-2
antispike-IgG
serology
ISSN:0146-6615, 1096-9071, 1096-9071
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:In a COVID‐19 sero‐surveillance cohort study with predominantly healthy and vaccinated individuals, the objectives were (i) to investigate longitudinally the factors associated with the quantitative dynamics of antispike (anti‐S1) IgG antibody levels, (ii) to evaluate whether the levels were associated with protection from SARS‐CoV‐2 infection, and (iii) to assess whether the association was different in the pre‐Omicron compared with the Omicron period. The QuantiVac Euroimmun ELISA test was used to quantify anti‐S1 IgG levels. The entire study period (16 months), the 11‐month pre‐Omicron period and the cross‐sectional analysis before the Omicron surge included 3219, 2310, and 895 reactive serum samples from 949, 919, and 895 individuals, respectively. Mixed‐effect linear, mixed‐effect time‐to‐event, and logistic regression models were used to achieve the objectives. Age and time since infection or vaccination were the only factors associated with a decline of anti‐S1 IgG levels. Higher antibody levels were significantly associated with protection from SARS‐CoV‐2 infection (0.89, 95% confidence interval [CI] 0.82–0.97), and the association was higher during the time period when Omicron was predominantly circulating compared with the ones when Alpha and Delta variants were predominant (adjusted hazard ratio for interaction 0.66, 95% CI 0.53–0.84). In a prediction model, it was estimated that >8000 BAU/mL anti‐S1 IgG was required to reduce the risk of infection with Omicron variants by approximately 20%–30% for 90 days. Though, such high levels were only found in 1.9% of the samples before the Omicron surge, and they were not durable for 3 months. Anti‐S1 IgG antibody levels are statistically associated with protection from SARS‐CoV‐2 infection. However, the prediction impact of the antibody level findings on infection protection is limited.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.28904